Liver
Viral Hepatitis (A/B/C)
Viral Hepatitis (A/B/C) is a liver-health topic that groups hepatitis A, hepatitis B, and hepatitis C under one heading. It refers specifically to viral hepatitis involving the liver, rather than to liver conditions in general.
Viral Hepatitis (A/B/C) brings three viral hepatitis types together under one liver-health topic.
This list shows research findings, not treatments. Nothing here replaces medical care. If you have this condition, talk to a doctor.
What may help
None of these options has good evidence yet. Best evidence first.
1 option:1 not enough evidence
FastingpracticeNot enough evidence
Too few or too small studies to know if it works.
The one study found a benefit.
A study of 202 patients found no significant effect of fasting on liver function tests, while medication adherence was better in the non-fasting group. The review stated that fasting was acceptable for people who were stable and adhered to antiviral therapy.
Open the Fasting page
The expert view shows every study, dose protocol and source.
What may help
Interventions recorded as helping with this condition1 listedThe best we have, but the evidence is still weak
- →PracticesFastingCertaintyLowSourceReview
A study of 202 patients found no significant effect of fasting on liver function tests, while medication adherence was better in the non-fasting group. The review stated that fasting was acceptable for people who were stable and adhered to antiviral therapy.
Who was studied
- People with a condition
- Cancer
- Fatty Liver Nafld
- Hepatitis Viral
Open FastingStudy result
An Egyptian study of 202 patients found fasting did not significantly affect liver function tests, but medication adherence was better in non-fasting group; recommendations state fasting is acceptable if stable with adherence to antiviral therapy.
What to avoid
Interventions recorded as making it worseNothing in this library is currently recorded as making Viral Hepatitis (A/B/C) worse. Coverage is partial, and absence here is not evidence of safety.
How to read the evidence
Evidence tier — overall strength of the evidence for the whole compound
- StrongWell established — backed by strong, consistent human research.
- ModerateSome genuine support, but mostly from small or lower-quality studies. Promising, not proven.
- PreliminaryEarly-stage evidence — a promising hypothesis, not an established effect yet.
- LimitedVery limited evidence — treat this as a hypothesis, not proof.
- InsufficientNot enough good evidence to draw conclusions yet.
Certainty — how sure we can be that the effect is real
- Very highVery sure — strong, consistent evidence
- HighFairly sure — consistent evidence from good studies
- MediumModerately sure — new studies could change this
- LowNot sure — little or mixed evidence
- Very lowVery unsure — almost no usable evidence
Source — where the data comes from
- Meta-analysisPooled analysis of many trials — the strongest evidence
- RCTRandomized controlled trial — a strong human study design
- ClinicalA human clinical study
- Reference knowledgeFrom general health-science or pharmacology references, not a study of this exact claim
- Animal researchStudied in animals, not humans
- Community reportsAggregated user reports — anecdotal signal, not evidence
- TheoreticalMechanism-based reasoning, not yet tested
Study grade — quality of each underlying study (A best, D weakest)
- AHigh-quality — strong, consistent human trials
- BGood — solid evidence with some limitations
- CModerate — limited, small, or mixed-quality studies
- DWeak — preliminary, indirect, or animal-only
Confidence — how strongly the sources back a finding
A 0–100 score from study quality and agreement
Most supplement evidence is graded C–D. Read it as preliminary signal, not proof.
Full write-up
What is it
Viral Hepatitis (A/B/C) is a liver-health topic that groups hepatitis A, hepatitis B, and hepatitis C under one heading. It refers specifically to viral hepatitis involving the liver, rather than to liver conditions in general. The related evidence considers several interventions in the context of this topic, including Milk Thistle (Silymarin), Green Tea Extract (EGCG), SAM-e, and Spirulina.
Evidence-backed options
The options associated with Viral Hepatitis (A/B/C) have been studied through different types of findings, including changes in liver function tests, ALT levels, viral activity, and liver-cell damage. These outcomes are not interchangeable: a change in a laboratory marker does not by itself establish an effect on the underlying viral infection or on longer-term disease outcomes.
The evidence is not uniform across the options. Findings for Green Tea Extract (EGCG) describe effects on hepatitis B and C virus entry and replication within hepatocytes, as well as on hepatitis-related inflammation. SAM-e has been associated with improved liver function tests and response rates compared with conventional symptomatic treatment. Spirulina has shown encouraging results in chronic HCV, but the findings specifically support larger and longer studies to confirm safety and efficacy. In contrast, neither dosage of Milk Thistle (Silymarin) significantly reduced ALT levels in the study described.
No shared dose, treatment duration, or onset of effects is established here, so the findings do not indicate how much was taken, for how long, or how quickly any change appeared. The evidence also does not establish that these options treat all forms of viral hepatitis equally; the described findings specifically mention hepatitis B and C or chronic HCV in some cases. These options therefore remain educational areas of investigation rather than interchangeable approaches, and medical evaluation is important for any form of viral hepatitis.